Portal de Periódicos da CAPES

Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial

2023; Elsevier BV; Volume: 8; Issue: 11 Linguagem: Inglês

10.1016/s2468-1253(23)00243-1

2468-1253

John V. Reynolds, Shaun R. Preston, Brian Patrick O’Neill, Maeve A. Lowery, Lene Bæksgaard, T. Crosby, Moya Cunningham, Sinéad Cuffe, Gareth Griffiths, Imelda Parker, Signe Lenora Risumlund, Rajarshi Roy, Stephen Falk, George B. Hanna, Frederick R. Bartlett, Alberto Alvarez‐Iglesias, Michael Patrick Achiam, Magnus Nilsson, Guillaume Piessen, Narayanasamy Ravi, Dermot O’Toole, Ciarán Johnston, Ray McDermott, Richard Turkington, Shajahan Wahed, Sharmila Sothi, Hugo Ford, Martin Wadley, Derek G. Power, Somnath Mukherjee, Carys Morgan, Simon L. Parsons, Neel Bhuva, Sorcha Campbell, Liam Grogan, Greg Leonard, Andrew Bateman, Catherine Mitchell, Séamus O’Reilly, Eibhlin Mulroe, Olivia McLoughlin, Anna Shevlin, Aoife M. Shannon, Jacinta Marron, Marc Nolan, Grace Burch, Michelle Costello, Daniel E. Griffiths, Kelly Cozens, Emma Foley, Claire L. Donohoe, Catherine O’Farrell, Jennifer E. Moore, Jacintha O’Sullivan,

Metastasis and carcinoma case studies

The optimum curative approach to adenocarcinoma of the oesophagus and oesophagogastric junction is unknown. We aimed to compare trimodality therapy (preoperative radiotherapy with carboplatin plus paclitaxel [CROSS regimen]) with optimum contemporaneous perioperative chemotherapy regimens (epirubicin plus cisplatin or oxaliplatin plus fluorouracil or capecitabine [a modified MAGIC regimen] before 2018 and fluorouracil, leucovorin, oxaliplatin, and docetaxel [FLOT] subsequently).